Download

Full Text

?

CITATIONS

? Total citations

? Recent citations

n/a Field Citation Ratio

n/a Relative Citation Ratio

publications

0

supporting

0

mentioning

0

contrasting

0

Smart Citations

0

0

0

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

• Haas R., Mohle R., Fruhauf S., Goldschmidt H., Witt B., Flentje M., Wannenmacher M., Hunstein W. (1993) Patients' characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphomas. Blood 12:3787.
• Schmitz N., Linch D.C., Dreger P., Goldstone A.H., Boogaerts M.A., Ferrant A., Demuunck H.M., Link H., Zander A., Barge A. (1996) Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353.
• Brice P., Marolleau J.P., Pautier P., Maake J., Cazals D., Dombret H., D'Agay M.F., Benbunan M., Gisselbrecht C. (1996) Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: Comparison of bone marrow and peripheral blood progenitor cells. Leukemia and Lymphoma 22:449.
• Weaver C.H., Hazelton B., Birch R., Palmer P., Allen C., Schwartzberg L., West W. (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961.
• Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K., Gooley T., Demirer T., Schiffman K., Weaver C. (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology 13:2547.
• Klumpp T.R., Mangan K.F., Golberg S.L., Pearlman E.S., Macdonald J.J. (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective randomized trial. Journal of Clinical Oncology 13:1323.
• Ketterer N., Salles G., Raba M., Espinousse D., Sonet A., Tremisi P., Dumontet C., Moullet I., Eljaafari-Corbin A., Neidhart E.M., Bouafia F., Coiffier B. (1998) High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 91:3148.
• Gisselbrecht C., Prentice H.G., Bacigalupo A., Biron P., Milpied N., Rubie H., Cunningham D., Legros M., Pico J.L., Linch D., Burnett A.K., Scarffe J.H., Siegert W., Yver A. (1994) Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 343:696.
• Spitzer G., Adkins D.R., Spencer V., Dunphy F.R., Petruska P.J., Velasquez W.S., Bowers C.E., Kronmueller N., Niemeyer R., McIntyre W. (1994) Randomized study of growth factors post-peripheral-blood-stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit. Journal of Clinical Oncology 12:661.
• Kawano Y., Takaue Y., Mimaya J., Horikoshi Y., Watanabe T., Abe T., Shimizu Y., Matsushita T., Kikuta A., Watanabe A., Iwai A., Ito E., Endo M., Kodani N., Ohta S., Gishi K., Azuma H., Etoh T., Okamoto Y., Amano K., Hattori H., Eguchi H., Kuroda Y. (1998) Marginal benefit/disadvantage of GCSF therapy after autologous blood stem cell transplantation in children: Results of a prospective randomised trial. Blood 92:4040.
• Gisselbrecht C., Lepage E., Morel P., Lederlin P., Coiffier B., Tilly H., Bosly A., Gabarre J., Briere J., Fillet G., Molina T., Reyes F. (1996) Intensified induction phase including autologous peripheral stem cell transplantation does not improve response rate and survival in poor prognosis aggressive lymphoma versus ACVB regimen. Blood , (abstract); 88:470.
• (1993) A predictive model for aggressive Non Hodgkin's lymphoma. New England Journal of Medicine , The International Non Hodgkin's Lymphoma Prognostic Factors Project.; 328:1002.
• Coiffier B., Gisselbrecht C., Herbrecht R., Tilly H., Bosly A., Brousse N. (1989) LNH-84 regimen, a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. Journal of Clinical Oncology 7:1018.
• Cox D.R. (1972) Regression model and life tables. Journal of the Statisticians Society 34:187.
• Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., Sonneveld P., Gisselbrecht C., Cahn J.Y., Harousseau J.L. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin's lymphoma. New England Journal of Medicine 333:1540.
• Watts M.J., Sullivan A.M., Jamieson E., Pearce R., Fieldings A., Devereux S., Goldstone A.H., Linch D.C. (1997) Progenitor-cell mobilization after low dose cyclophosphamide and granulocyte colony stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 malignant lymphoma. Journal of Clinical Oncology 15:535.
• Barbui T., Cortelazzo S., Rossi A. (1996) Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma. Cancer Chemotherapeutic and Pharmacology 38(SUPPL.):110.
• Siena S., Bregni M., Brando B., Belli N., Ravagnani F., Gandola L., Stern A.C., Landsorp P.M., Bonadonna G., Gianni A.M. (1991) Flow cytometry clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400.
• Haas R., Witt B., Möhle R., Goldschmidt H., Hohaus S., Fruehauf S., Wannenmacher M., Hunstein W. (1995) Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 85:3754.
• Schwella N., Siegert W., Beyer J., Rick O., Zingsen J., Eckstein R., Sehse S., Huhn D. (1995) Autografting with blood progenitor cells: Predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. Annals of Hematology 71:227.
• Schulman K., Birch R., Zhen B., Pania N., Weaver C. (1999) Effect of CD34+ cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. Journal of Clinical Oncology 17:1227.
• McQuaker I.G., Hunter A.E., Pacey S., Haynes A.P., Iqbal A., Russel N.H. (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lympho-proliferative disorders: Evidence for clinical and economic benefit. Journal of Clinical Oncology 15:451.
• Linch D.C., Milligan D.W., Winfield D.A., Keenau R.D., Goldstone T. (1995) G-CSF significantly accelerates neutrophil recovery after peripheral blood stem cell transplantation (PBCT) in lymphoma patients and shortens the time in hospital; preliminary results of a randomised BNLI trial. Blood , abstract; 86(SUPPL. 1):873.
• Ojeda E., Bustos-Garcia J., Aguado M.J., Hernandes-Navarro F. (1998) A randomized study of filgrastim (G-CSF) after autologous peripheral blood transplantation. Blood , abstract; 92(SUPPL. 1):4403.
• Klumpp T., Sullivan E., Ackerman S., Reblando J.A., Bleecker G.C., Mangan K.F. (1998) Cost analysis of a randomized trial comparing G-CSF to standard supportive care following PBSC transplantation. Blood , abstract; 92(SUPPL. 1):528.
• Shea T., Wiley J., Serody J., Gabriel D., Powell E., Bigelow S., Schultz S., Brecher M., Bentley S., Lin Y., Schell M. (1998) Fixed dose G-CSF post autologous peripheral blood stem cell transplantation (PBSCT) permits utilization of lower doses of growth factor without compromising engraftment. Blood , abstract; 92(SUPPL.):525.
• Colby C., McAfee S., Finkelstein D., Spitzer T.R. (1998) Early vs delayed addition of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 21:1005.
• Bence-Bruckler I., Bredeson C., Atkinss H., McDiarmid S., Hamelin L., Hopkins H., Perry G., Genest P., Huebsch L. (1998) A randomized trial of G-CSF (neupogen) starting day 1 vs day 7 post autologous stem cell transplantation. Bone Marrow Transplantation 22:965.
• Bolwell B., Goormastic M., Dannley R., Andresen S., Overmoger B., Mendez Z., Kalaycoglu M., Demars D., Wise K., Pohlman B. (1997) G-CSF post-autologous progenitor cell transplantation: A randomized study of 5, 10, and 16 υg/kg/day. Bone Marrow Transplantation 19:215.